Clinical Trial Update: Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating EC145 in combination with Doxil for platinum-resistant ovarian cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Doxil (liposomal doxorubicin)
• EC145 (vintafolide)

Snippet

Sponsor: Endocyte | Conditions: Ovarian Cancer | Phase 3 | Status: TERMINATED